The Global HIV Injection Market size is expected to reach $2.8 billion by 2030, rising at a market growth of 17.6% CAGR during the forecast period.
North America, particularly the United States, has a relatively high prevalence of HIV compared to other regions. Therefore, the North America segment captured $368.07 million revenue in the market in 2022. This high prevalence creates a substantial demand for HIV medications, including injectable therapies. North America is at the forefront of HIV research and treatment, leading to the development of new and innovative HIV medications, including injectable therapies.
The escalating prevalence of HIV/AIDS necessitates the development of more efficacious treatment modalities to alleviate symptoms and sustain life. This increased demand has driven pharmaceutical companies and researchers to develop new and innovative HIV injections to meet the growing needs of patients. Thus, the increasing prevalence of HIV is supporting the growth of the market.
Additionally, the innovative formulations offer several advantages over traditional oral medications, driving their adoption and increasing demand in the market. Injectable therapies typically require less frequent dosing than oral medications, which can be particularly beneficial for patients with difficulty adhering to complex medication schedules. Therefore, the development of innovative injectable formulations for the treatment of HIV/AIDS has had a positive impact on the demand for HIV injections.
However, the high cost of HIV treatment, including injectable medications, remains a significant barrier to access for many people living with HIV/AIDS, particularly in low- and middle-income countries. The cost of HIV treatment can include not only the price of the medication itself but also the cost of regular monitoring, laboratory tests, and healthcare provider visits, which can quickly add up to a substantial financial burden for patients. Hence, the high cost might hamper the expansion of the market.
The COVID-19 pandemic had a significant impact on the market, affecting various aspects of the supply chain and patient access to treatment. Raw material shortages and manufacturing delays followed disruptions in the global supply chain, which affected HIV medications, including injectable therapies. These disruptions impacted their availability in some regions, potentially leading to treatment interruptions for patients. Thus, the pandemic affected the market negatively
North America, particularly the United States, has a relatively high prevalence of HIV compared to other regions. Therefore, the North America segment captured $368.07 million revenue in the market in 2022. This high prevalence creates a substantial demand for HIV medications, including injectable therapies. North America is at the forefront of HIV research and treatment, leading to the development of new and innovative HIV medications, including injectable therapies.
The escalating prevalence of HIV/AIDS necessitates the development of more efficacious treatment modalities to alleviate symptoms and sustain life. This increased demand has driven pharmaceutical companies and researchers to develop new and innovative HIV injections to meet the growing needs of patients. Thus, the increasing prevalence of HIV is supporting the growth of the market.
Additionally, the innovative formulations offer several advantages over traditional oral medications, driving their adoption and increasing demand in the market. Injectable therapies typically require less frequent dosing than oral medications, which can be particularly beneficial for patients with difficulty adhering to complex medication schedules. Therefore, the development of innovative injectable formulations for the treatment of HIV/AIDS has had a positive impact on the demand for HIV injections.
However, the high cost of HIV treatment, including injectable medications, remains a significant barrier to access for many people living with HIV/AIDS, particularly in low- and middle-income countries. The cost of HIV treatment can include not only the price of the medication itself but also the cost of regular monitoring, laboratory tests, and healthcare provider visits, which can quickly add up to a substantial financial burden for patients. Hence, the high cost might hamper the expansion of the market.
The COVID-19 pandemic had a significant impact on the market, affecting various aspects of the supply chain and patient access to treatment. Raw material shortages and manufacturing delays followed disruptions in the global supply chain, which affected HIV medications, including injectable therapies. These disruptions impacted their availability in some regions, potentially leading to treatment interruptions for patients. Thus, the pandemic affected the market negatively
By Distribution Channel Analysis
Based on distribution channel, the market is divided into hospital pharmacy, drug stores & retail pharmacies, and others. The hospital pharmacy segment procured 46.2% revenue share in the market in 2022. Hospitals, clinics, and other healthcare facilities are major distribution points for HIV injections. They receive medications from pharmaceutical companies or wholesalers and distribute them to patients as part of their treatment regimens.
By Regional Analysis
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The LAMEA segment witnessed 5.3% revenue share in the market in 2022. The LAMEA region has a relatively high prevalence of HIV, with certain countries in sub-Saharan Africa experiencing particularly high rates of infection. Governments in the LAMEA region have implemented various initiatives to address the HIV/AIDS epidemic, including funding for HIV/AIDS programs and improving access to treatment.List of Key Companies Profiled
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F.Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Market Report Segmentation
By Distribution Channel- Hospital Pharmacy
- Drugs Stores & Retail Pharmacies
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global HIV Injection Market by Distribution Channel
Chapter 5. Global HIV Injection Market by Region
Chapter 6. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F. Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Methodology
LOADING...
